HIV rebounds from latently infected cells, rather than from continuing low-level replication
Top Cited Papers
- 28 October 2008
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (43), 16725-16730
- https://doi.org/10.1073/pnas.0804192105
Abstract
Rapid rebound of plasma viremia in patients after interruption of long-term combination antiretroviral therapy (cART) suggests persistence of low-level replicating cells or rapid reactivation of latently infected cells. To further characterize rebounding virus, we performed extensive longitudinal clonal evolutionary studies of HIVenvC2-V3-C3 regions and exploited the temporal relationships of rebounding plasma viruses with regard to pretreatment sequences in 20 chronically HIV-1-infected patients having undergone multiple 2-week structured treatment interruptions (STI). Rebounding virus during the short STI was homogeneous, suggesting mono- or oligoclonal origin during reactivation. No evidence for a temporal structure of rebounding virus in regard to pretreatment sequences was found. Furthermore, expansion of distinct lineages at different STI cycles emerged. Together, these findings imply stochastic reactivation of different clones from long-lived latently infected cells rather than expansion of viral populations replicating at low levels. After treatment was stopped, diversity increased steadily, but pretreatment diversity was, on average, achieved only >2.5 years after the start of STI when marked divergence from preexisting quasispecies also emerged. In summary, our results argue against persistence of ongoing low-level replication in patients on suppressive cART. Furthermore, a prolonged delay in restoration of pretreatment viral diversity after treatment interruption demonstrates a surprisingly sustained evolutionary bottleneck induced by punctuated antiretroviral therapy.Keywords
This publication has 72 references indexed in Scilit:
- Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapyProceedings of the National Academy of Sciences, 2008
- Productive Human Immunodeficiency Virus Type 1 Infection in Peripheral Blood Predominantly Takes Place in CD4/CD8 Double-Negative T LymphocytesJournal of Virology, 2007
- Interruption of Antiretroviral Therapy Initiated during Primary HIV-1 Infection: Impact of a Therapeutic Vaccination Strategy Combined with Interleukin (IL)-2 Compared with IL-2 Alone in the ANRS 095 Randomized StudyAIDS Research and Human Retroviruses, 2007
- Long‐Term Persistence of Transmitted HIV Drug Resistance in Male Genital Tract Secretions: Implications for Secondary TransmissionThe Journal of Infectious Diseases, 2007
- Nuclear Retention of Multiply Spliced HIV-1 RNA in Resting CD4+ T CellsPLoS Pathogens, 2006
- Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4 + T CellsJournal of Virology, 2006
- Limited Durability of Viral Control following Treated Acute HIV InfectionPLoS Medicine, 2004
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995